M M Avram

State University of New York Downstate Medical Center, Brooklyn, New York, United States

Are you M M Avram?

Claim your profile

Publications (107)487.38 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Elevated levels of serum alkaline phosphatase (AlkPhos) have been reported to be associated with increased mortality risk in hemodialysis (HD) patients. We examined the association of serum AlkPhos with all-cause mortality in our PD patients. The study enrolled 90 PD patients beginning in 1995. On enrollment, demographics and clinical and biochemical data were recorded. Patients were followed to September 2011. Mean age of the enrollees was 52 years, with 61% being women, and most (81%) being of African descent. Mean and median AlkPhos were 135 U/L and 113 U/L respectively. Mean and maximum follow-up were 2.61 and 16 years respectively. As expected, AlkPhos correlated directly with serum intact parathyroid hormone (r = 0.36, p = 0.003). In a Cox multivariate regression analysis with adjustment for confounding variables, AlkPhos as a continuous (relative risk: 1.016; p = 0.004) anda categorical variable [> 120 U/L and < or = 120 U/L (relative risk: 6.0; p = 0.03)] remained a significant independent predictor of mortality. For each unit increase in enrollment AlkPhos, there was a 1.6% increase in the relative risk of death. Elevated serum AlkPhos is significantly and independently associated with increased mortality risk in our PD patients followed for up to 16 years. AlkPhos should be evaluated prospectively as a potential therapeutic target in clinical practice.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 01/2013; 29:61-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between dialysis vintage (length of time on dialysis), body composition, and survival has been reported in hemodialysis patients. In the present study, we examined the association ofdialysis vintage with body composition and survival in peritoneal dialysis (PD) patients. At enrollment, body composition in 65 PD patients was determined by bioelectrical impedance analysis. Patients (mean age at enrollment: 54 years) were followed for up to 11 years maximum. At enrollment, the mean, median, and maximum dialysis vintages were 51, 34, and 261 months respectively. After adjusting for age, race, sex, and diabetes status, dialysis vintage was indirectly correlated (partial correlation coefficients) with body weight (r = -0.40, p = 0.001), body mass index (r = -0.40, p = 0.002), body surface area (r = -0.39, p = 0.002), body cell mass (r = -0.39, p = 0.002), total body fat weight (r = -0.30, p = 0.02), and fat percentage of body weight (r = -0.31, p = 0.018), and directly correlated with extracellular mass to body cell mass ratio (r = 0.27, p = 0.039). The observed cumulative survival was significantly higher (p = 0.007) in patients with a dialysis vintage at enrollment of 35 months or less, than in patients with dialysis vintage at enrollment of more than 35 months. In the multivariate Cox regression analysis, adjusting for age, race, sex, and diabetes, dialysis vintage at enrollment remained an independent predictor of mortality (relative risk: 1.010; p = 0.002). Increase in relative risk of death with increasing dialysis vintage may be partly explained by the association of vintage with unfavorable changes in body composition and the nutrition status of patients over time.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 01/2012; 28:144-7.
  • American Journal of Kidney Diseases - AMER J KIDNEY DIS. 01/2011; 57(4).
  • American Journal of Kidney Diseases - AMER J KIDNEY DIS. 01/2011; 57(4).
  • Morrell M Avram
    Kidney international. Supplement 08/2010;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malnutrition is a strong predictor of mortality in peritoneal dialysis (PD) patients. Extracellular mass (ECM) contains all the metabolically inactive, whereas body cell mass (BCM) contains all the metabolically active, tissues of the body. ECM/BCM ratio is a highly sensitive index of malnutrition. The objective of this study was to explore the relationship between ECM/BCM ratio and survival in PD patients. We enrolled 62 patients from November 2000 to July 2008. On enrollment, demographic, clinical, and biochemical data were recorded. Bioimpedance analysis (BIA) was used to determine ECM and BCM in PD patients. Patients were followed up to November 2008. Mean age was 54+/-16 (s.d.) years; female, 55%; African Americans, 65%; diabetic, 24%. Mean ECM/BCM ratio was 1.206+/-0.197 (range: 0.73-1.62). Diabetics had higher ECM/BCM ratio than nondiabetics (1.29 vs 1.18, P=0.04). ECM/BCM ratio correlated directly with age (r=0.38, P=0.002) and inversely with serum albumin (r=-0.43, P=0.001), creatinine (-0.24, P=0.08), blood urea nitrogen (r=-0.26, P=0.06), and total protein (r=-0.31, P=0.026). Using multivariate Cox regression analysis, adjusting for age, race, gender, diabetes, and human immunodeficiency virus status, enrollment ECM/BCM ratio was a significant independent predictor of mortality (relative risk=1.035, P=0.018). For every 10% increase in the ECM/BCM ratio, the relative risk of death was increased by about 35%. In conclusion, BIA-derived enrollment ECM/BCM ratio, a marker of malnutrition, was an independent predictor of long-term survival in PD patients.
    Kidney international. Supplement 08/2010;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is the most common cause of end-stage renal disease and an important risk factor for morbidity and mortality in dialysis patients. Glycemic control, utilizing serial measurement of glycosylated hemoglobin (HbA1c), is generally recommended to limit end-organ damage, including cardiovascular morbidity and mortality. We, along with others, have previously suggested that HbA1c may not be a reliable measure of glycemic control in dialysis patients, and have therefore explored the use of serum fructosamine (SF) as an alternative marker. The objective of this study was to compare HbA1c levels with SF in monitoring glycemic control and associated morbidity (infection and hospitalization) in diabetic patients in a large urban hemodialysis (HD) center. We enrolled 100 diabetic HD patients and followed them up prospectively for 3 years. Data on demographics, as well as biochemical and clinical data, including hospitalizations and infections, were recorded. The mean age was 63 years. In all 54% were women and the majority were African Americans (72%). As expected, HbA1c and albumin-corrected fructosamine (AlbF) levels were highly correlated and both were significantly associated with serum glucose. AlbF, however, was more highly correlated with mean glucose values when less than 150 mg/dl and was a more useful predictor of morbidity. By univariate logistic regression and by Poisson regression analysis, AlbF, but not HbA1c, was a significant predictor of hospitalization. Additionally, in patients dialyzed by arteriovenous (AV) access (that is, excluding those dialyzed via vascular catheters), AlbF, but not HbA1c, was a significant predictor of infection. In conclusion, AlbF is as reliable a marker as HbA1c for glycemic control in diabetic patients on HD, and may be advantageous for patients with serum glucose in a desirable therapeutic range (<150 mg/dl). In addition, AlbF, but not HbA1c, is associated with morbidity (hospitalizations and infections) in diabetic patients on HD.
    Kidney international. Supplement 08/2010;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. The management of SHPT commonly involves vitamin D, either calcitriol or newer analogs (paricalcitol or doxercalciferol), along with dietary phosphorus restriction and phosphate binding agents. Published reports have suggested that treatment with paricalcitol in hemodialyzed (HD) patients offers a morbidity or mortality advantage in comparison with treatment with calcitriol. We have recently reported that switching from calcitriol to paricalcitol resulted in a lower serum calcium and calcium-phosphorus product (Ca x P product), as well as lower parathyroid hormone (PTH) and alkaline phosphatase during 6 months of serial treatment. We converted all HD patients in our large urban dialysis center from calcitriol to paricalcitol using a 1:3 conversion ratio, on the basis of published data. Comparisons of individual patient mean biochemical values, as well as episodes of hypercalcemia and elevated Ca x P product, were made after adjusting for equivalent doses. In addition, we recorded the number of missed doses during two years of therapy. No patient in this study had received a calcimimetic before or during the study period. Fifty-nine patients were treated with calcitriol for at least 12 months and then completed 12 months of paricalcitol. Conversion from calcitriol to paricalcitol resulted in lower serum calcium (P=0.0003), lower serum phosphorus (P=0.027), lower Ca x P product (P=0.003), reduced PTH (P=0.001) and reduced serum alkaline phosphatase (P=0.0005). Most dramatically, there was a highly significant difference in the number of missed doses (P<0.0001) during the treatments. This 2-year single-center study, comparing long-term calcitriol with paricalcitol treatment in the same HD patients, extends our previous findings, offers new information regarding single episodes of potentially adverse biochemical effects related to vitamin D therapy, and provides several clues that may explain the outcome advantages suggested by previously published retrospective analyses of large dialysis provider-pooled databases.
    Kidney international. Supplement 08/2010;
  • Morrell M Avram
    Kidney International 08/2010; · 8.52 Impact Factor
  • American Journal of Kidney Diseases - AMER J KIDNEY DIS. 01/2010; 55(4).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fluid overload is a common complication in peritoneal dialysis (PD) patients. The prognostic importance of enrollment fluid status in long-term PD patients remains to be investigated. The objective of the present study was to investigate the prognostic importance of enrollment fluid status in the long-term survival of PD patients. We enrolled 53 PD patients (mean age: 53 years) from November 2000 to February 2006. On enrollment, demographic, clinical, and biochemical data were recorded. Bioelectrical impedance analysis (BIA) was used to determine the fluid status of PD patients, including extracellular water (ECW), intracellular water (ICW), and total body water (TBW). Fluid status was corrected for body surface area (BSA): ECW-BSA, ICW-BSA, and TBW-BSA respectively. Patients were followed to January 2008. The ECW-BSA correlated negatively with albumin, a marker of nutrition (r = -0.53, p < 0.0001). The ICW/ECW ratio (r = 0.36, p = 0.018) correlated directly and the ECW/ TBW ratio (r = -0.36, p = 0.019) correlated negatively with creatinine. Patients who survived during the study period had a significantly lower ECW-BSA (8.29 L/m2 vs. 9.91 L/m2, p = 0.001) than did those who did not survive. Patients with enrollment ECW-BSA below 9 L/m2 had a significantly better 7-year cumulative survival (Kaplan-Meier) than did patients with a ECW-BSA of 9 L/m2 or more (p = 0.019). Using multivariate Cox regression analysis, adjusting for age, race, diabetes, human immunodeficiency virus (HIV) status, and months on dialysis at enrollment, ECW-BSA was a significant independent predictor of mortality (relative risk: 1.50; p = 0.03). In conclusion, ECW-BSA was a significant independent predictor of long-term survival in PD patients.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 02/2008; 24:79-83.
  • American Journal of Kidney Diseases - AMER J KIDNEY DIS. 01/2008; 51(4).
  • Morrell M. Avram, Daniel A. Blaustein
    Seminars in Dialysis 09/2007; 10(5):267 - 271. · 2.25 Impact Factor
  • D A Blaustein, M M Avram
    Kidney International 06/2007; 72(2):225-225. · 8.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The information available in the literature regarding pulmonary hypertension (PH) in peritoneal dialysis (PD) patients is limited. The objective of the present study was to examine the prevalence and characteristics of PH in PD patients. We retrospectively collected the clinical profile, echocardiographic (ECHO) findings, and biochemical data for 36 PD patients for which ECHO findings were available. We compared characteristics between patients with and without PH. We found PH, defined as pulmonary arterial pressure (PAP) > or = 35 mmHg, in 15 patients. The prevalence of PH was 42%. Mean age (+/- standard deviation) of the patients with and without PH was 58 +/- 15 years and 52 +/- 15 years respectively (p = 0.30). Mean PAP of the PH patients was 43.8 +/- 9.0 mmHg (range: 35-65 mmHg). Patients with PH had a lower ejection fraction than did patients without PH (46.3% +/- 19.8% vs. 56.5% +/- 11.8% respectively, p = 0.07). Patients with PH also had a higher prevalence of global hypokinesia (60% vs. 29%, p = 0. 059) and dilated left ventricular chamber (53% vs. 19%, p = 0.03). In PH patients, body mass index (24 +/- 4.5 kg/m2 vs. 28 +/- 5.0 kg/m2, p = 0.024), normalized protein catabolic rate (0. 78 +/- 0.21 g/kg vs. 0.95 +/- 0.27 g/kg daily, p = 0.049), and ferritin (226 +/- 210 ng/mL vs. 873 +/- 965 ng/mL, p = 0.005) were significantly lower and lactate dehydrogenase was higher (264 +/- 99 U/L vs. 206 +/- 79 U/L, p = 0.06) than in patients without PH. We observed no significant differences in race or sex, incidence of hypertension or cardiovascular disease, or vitamin D analog use between the two groups of patients. During the study period, 60% of PH patients and 38% of patients without PH died (p = 0.19). Values of PAP correlated directly with serum levels of phosphorus (r = 0.44, p = 0.02), CaxP product (r = 0.40, p = 0.04), and parathyroid hormone (r = 0.42, p = 0.03). Of continuous ambulatory PD and continuous cycling PD patients, 21% and 55% respectively had PH (p = 0. 049). In PD patients, PH is highly prevalent and may be associated with higher mortality risk.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 01/2007; 23:127-31.
  • Source
    M M Avram
    Kidney International 11/2006; · 8.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. The medical management of SHPT in hemodialysis (HD) patients commonly utilizes intravenously administered vitamin D, either calcitriol or newer analogs (paricalcitol or doxercalciferol). Recent published reports have suggested that the use of paricalcitol in HD patients offers a morbidity or mortality advantage in comparison to treatment with calcitriol. The objective of this study was to compare the biochemical markers of SHPT during serial treatment with calcitriol and paricalcitol. We converted all HD patients in our large urban dialysis center from calcitriol to paricalcitol using a 1:3 conversion ratio, based on published data. Demographic, clinical, and laboratory data were collected, and comparisons of individual patient mean values were made after adjusting for equivalent doses. In addition, we recorded the number of missed doses during 6 months of therapy with calcitriol and with paricalcitol. Seventy-three patients were treated with calcitriol for at least 6 months before conversion to paricalcitol, and then completed 6 months of treatment with paricalcitol. Converting from calcitriol to paricalcitol resulted in lower serum calcium (P=0.048), lower calcium-phosphorus product (P=0.014), reduced biointact parathyroid hormone (P=0.029), and reduced serum alkaline phosphatase (P=0.0002). Most dramatically, there was a highly significant difference in the number of missed doses (P<0.0001). This study, the first comparing long-term calcitriol to paricalcitol treatment in the same HD patients, offers several important clues that may explain outcome differences reported in large pooled reports.Keywords: secondary hyperparathyroidism, parathyroid hormone, vitamin D, end-stage renal disease, hemodialysis
    Kidney International 11/2006; · 8.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is necessary to provide adequate amounts of bioavailable iron to correct any deficit and maintain body iron stores in anemic patients with chronic kidney disease (CKD). Although dosing regimens for intravenous iron sucrose exist, simplification of these regimens may produce financial savings and reduce the time commitment of both patients and clinicians. We have explored high-dose (500 mg or greater) intravenous iron sucrose regimens in patients with CKD and summarize our findings here. Three studies used 500 mg intravenous iron sucrose doses on 2 or more successive days, and one study examined the feasibility of a single total dose infusion of 1000 mg. We conclude that patients do not tolerate 1000 mg doses as a single infusion. On the other hand, a dosing regimen of 500 mg iron sucrose given intravenously over 3 h on successive days is safe and effective in replenishing and maintaining body iron stores. Finally, in anemic CKD patients not receiving erythropoietic hormone therapy, we found an increase in hemoglobin concentrations, and no deleterious effect on glomerular filtration rate 6 months after they were treated with iron sucrose.Keywords: anemia, chronic kidney disease, iron sucrose, ferritin, hemoglobin, therapy
    Kidney International 11/2006; · 8.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation, dialysis adequacy, and peritoneal transport rate (PTR) influence clinical outcomes in peritoneal dialysis (PD) patients. The present study examined the relationship of C-reactive protein (CRP), a marker of inflammation, to PTR and residual renal function (RRF) in PD patients. We recorded the baseline dialysate-to-plasma creatinine (D/P Cr) of 210 PD patients starting in 1986. In a subgroup of 42 patients, we serially measured high-sensitivity CRP levels and.dialysis adequacy, including weekly Kt/V urea and creatinine clearance (CCr), starting in May 2003. The patients were followed to January 2006. Mean age was 53 +/- 16 (standard deviation) years, and 70% of the patients were African American. Enrollment mean and median CRP levels were 13.53 +/- 20.8 (range: 0.2-95.8) and 7.15 mg/L respectively. Mean weekly residual CCr and Kt/V during follow-up were 7.11 +/- 15.47 L/1.73 m2 and 0.14 +/- 0.30 respectively. The mean enrollment D/P Cr was 0.649 +/- 0.12 (range: 0.429-0.954). Patients with CRP > 10 mg/L had significantly lower weekly residual CCr (0.59 L/1.73 m2 vs. 10.1 L/1.73 m2, p = 0.01), residual Kt/V (0.01 vs. 0.20, p = 0.01), total CCr (56 L/1.73 m2 vs. 62 L/1.73 m2, p= 0.047), and total Kt/V (2.09 vs. 2.49, p = 0.001) than did those with CRP < or = 10 mg/L. Levels of CRP correlated negatively with weekly residual CCr (r = -0.42, p = 0.006), residual Kt/V (r = -0.43, p = 0.006), and total Kt/V (r = -0.44, p = 0.004). Enrollment D/P Cr was inversely correlated with serum albumin (r = -0.24, p = 0.001) and directly correlated with peritoneal protein loss (r = 0.34, p = 0.028). Higher enrollment D/P Cr was associated with lower observed cumulative survival (Kaplan-Meier) in PD patients. However D/P Cr was not an independent predictor of long-term survival in PD patients. Using multivariate Cox regression analysis, and including D/P Cr and residual Kt/V in the model, enrollment CRP was an independent predictor of mortality (relative risk = 1.036, p = 0.018). We conclude that elevated CRP is associated with lower RRF As a predictor of mortality, CRP may be better than RRF and D/P Cr.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 02/2006; 22:2-6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nutritional status is associated with clinical outcomes in dialysis patients. Inflammation may cause malnutrition and increases the risk of poor outcomes. We have investigated the relationship between nutritional markers, an inflammatory marker, and survival in 177 peritoneal dialysis (PD) patients, enrolled from 1991 to 2005. In 53 patients, bioimpedance analysis (BIA) measurements were conducted from November 2000. In a subgroup of 42 patients, we measured high-sensitivity C-reactive protein (CRP) and various nutritional markers including prealbumin serially from May 2003. All the patients were followed to April 2006. Mean enrollment albumin and prealbumin levels were 3.61±0.51 g/dl and 35.8±11.3 mg/dl, respectively. Mean and median enrollment CRPs were 13.53±20.81 (s.d.) and 7.15 mg/l, respectively. Higher enrollment levels of nutritional markers such as albumin (P
    Kidney International 01/2006; · 8.52 Impact Factor

Publication Stats

2k Citations
487.38 Total Impact Points

Institutions

  • 2012
    • State University of New York Downstate Medical Center
      Brooklyn, New York, United States
  • 2003–2010
    • Beth Israel Medical Center
      New York City, New York, United States
  • 2002–2007
    • State University of New York
      New York City, New York, United States
  • 1996
    • New York Medical College
      • Department of Medicine
      New York City, NY, United States